Targeting to macrophages: Role of physicochemical properties of particulate carriers - Liposomes and microspheres - On the phagocytosis by macrophages

Journal of Controlled Release

Volumn 79, Issue 1-3, 2002, Pages 29-40

  Ahsan, Fakhrul ^a   Rivas, Isabel P ^b   Khan, Mansoor A ^a   Torres Suárez, Ana I ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Liposomes; Macrophages; Microspheres; Physicochemical properties; Targeting

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; AZITHROMYCIN; CEPHALOSPORIN DERIVATIVE; CHOLESTEROL; CIPROFLOXACIN; CLODRONIC ACID; DIDANOSINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FIBRONECTIN; FOSCARNET; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; INTERLEUKIN 2; LIGAND; LIPOSOME; MICROSPHERE; MURAMYL DIPEPTIDE; MURAMYL TRIPEPTIDE; NANOPARTICLE; PENICILLIN DERIVATIVE; SPARFLOXACIN; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ARTHRITIS; CANCER; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; HYDROPHILICITY; IMMUNE SYSTEM; LEISHMANIASIS; MACROPHAGE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE;

ANIMALS; CHEMISTRY, PHYSICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MACROPHAGES; MICROSPHERES; PHAGOCYTOSIS;

EID: 0037133126     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00549-1     Document Type: Review

References (113)

1. The macrophage
2. The basis for the immunoregulatory role of macrophages and other accessory cells
3. Targeting of immunomodulators to mononuclear phagocytes for therapy of cancer
4. Functions of the human mononuclear phagocyte system
5. Detection of mediator derived from endotoxin stimulated macrophages that induces the acute phase serum myeloid A response in mice
6. Haematopoietic growth factors
7. Secretion of specific collagenase by stimulated macrophages
8. Modulation of endothelial cell haemostatic properties by tumour necrosis factor
9. The role of monocyte in atherogenesis. I. Transition of blood borne monocytes into foam cells in fatty lesions
10. Interleukin 1 is an astroglial growth factor in the developing brain
11. Immunity in bacterial infections
12. Tissue-directed antibiotics and intracellular parasites: Complex interaction of phagocyte, pathogens and drugs
13. Tumor associated macrophages: Disordered function, immune suppression and progressive tumor growth
14. Drug targeting
15. Long circulating and target specific nanoparticles: Theory to practice
16. Specialized drug delivery systems, manufacturing and production technology
17. Liposomes as carriers of antigens and adjuvants
18. Clinical application of liposomes containing macrophage activators for therapy of cancer metastasis
19. Liposomes as immunological adjuvants and vaccine carriers
20. Immunoliposomes: A promising approach to targeting cancer therapy
21. Liposomal encapsulated anthracyclines: New therapeutic horizons
22. Liposomes as targetable drug carriers
23. Systemic macrophage activation with liposome-entrapped immunomodulators for therapy of cancer metastasis
24. Biochemical, morphological and ultrastructural studies on the uptake of liposomes by murine macrophages
25. Interactions of liposome with reticulo-endothelial system. II. Non specific and receptor mediated uptake of liposomes by mouse peritoneal macrophages
26. The effect of liposome size and surface charge on liposome mediated delivery of methotrexate-γ-asparate to cells in vitro
27. Uptake of liposomes by cultured mouse bone marrow macrophages: Influence of liposome composition and size
28. The effects of charge and size on the interaction of unilamellar liposomes with macrophages
29. Differential uptake of liposomes varying in size and lipid composition by parenchymal and kupffer cells of mouse liver
30. Effect of lipid composition on the activity of liposome-entrapped ampicillin against intracellular Listeria monocytogenes
31. Effects of liposome structure and lipid composition on the activation of the tumouricidal properties of macrophages by liposomes containing muramyl dipeptide
32. Liposomal technology in cancer therapy
33. Accumulation of protein loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice
34. New synthetic amphiphilic polymers for steric protection of liposomes in vivo
35. Polymer coated long circulating microparticulate pharmaceuticals
36. Affinity liposomes in vivo: Factors influencing target accumulation
37. A novel peptide-grafted liposome delivery system targeted to macrophages
38. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors
39. Virosomes: Evolution of the liposomes as a targeted drug delivery system
40. Liposome as immunological adjuvants: Approaches to immunopotentiation including ligand-mediated targeting to macrophages
41. Activation of Fc receptor mediated phagocytosis by mouse peritoneal macrophages following the intraperitoneal administration of liposomes
42. Neoglycosylated liposomes as efficient ligand for the evaluation of specific sugar receptors on macrophages in health and in experimental leishmaniasis
43. Distribution of liposomes containing mannobiose esters of fatty acid in rats
44. Characterisation of mannosylphospholipid liposome system for drug targeting to alveolar macrophages
45. Neo-mannosylated liposomes: Synthesis and interaction with mouse kupffer cells and resident peritoneal macrophages
46. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis
47. Preparation and characterisation of liposome containing mannosylated phospholipids capable of targeting to macrophages
48. Interaction of immunoglobulin-coupled liposomes with rat liver macrophages in vitro
49. Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages
50. Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophage
51. Phagocytosis by macrophages of liposomes covered with fibronectin
52. Recognition of charged liposomes by rat peritoneal and splenic macrophages: Effects of fibronectin on the uptake of charged liposomes
53. Preparation of neo-galactosylated liposomes and their interaction with mouse peritoneal macrophages
54. Drug-loaded nanoparticles - Preparation methods and drug targeting issues
55. Controlled drug delivery with nanoparticles: Current possibilities and future trends
56. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) PLGA devices
57. Increase in gentamicin uptake by cultured mouse peritoneal macrophages and rat hepatocytes by its binding to polybutylcyanoacrylate nanoparticles
58. Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages
59. Phagocytosis of polymer microspheres by macrophages
60. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage
61. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats
62. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: A possibility for antiviral drug targeting
63. Influence of surface properties at biodegradable microsphere surfaces: Effects of plasma protein adsorption and phagocytosis
64. Antisense oligonucleotide delivery to cultured macrophages is improved by incorporation into sustained-release biodegradable polymer microspheres
65. Phagocytosis of bioactive microspheres
66. Synthesis of gelatin microspheres containing interferon
67. Phagocytic uptake by peritoneal macrophages of microspheres coated with phosphocholine or polyethylene glycol phosphate-derived perfluoroalkylated surfactants
68. Site specific microencapsulated drug targeting strategies - Liver and gastro-intestinal tract targeting
69. Delivery of IL-1 microspheres to tumor macrophages
70. Implication of activation of intraperitoneal macrophages with biodegradable microspheres
71. Interaction of microspheres with blood constituents. III. Macrophage phagocytosis of various types of polymeric drug carriers
72. Biodegradable microspheres V: Stimulation of macrophages with microparticles made of various polysaccharides
73. Endocytosis
74. Phagocytosis as a surface phenomenon
75. Analogous recognition of phospholipids by insect phagocytes and mammalian macrophages (42339)
76. Recognition of macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups
77. Phospholipid vesicle targeting using synthetic glycolipid and other determinants
78. The potential use of liposome mediated antiviral therapy
79. Liposomes as delivery systems in the presentation and treatment of infectious disease
80. Inhibitory effect of liposomal MDP-Lys on lung metastasis of transplantable osteosarcoma in hamster
81. Liposomes as drug delivery system: A strategic approach for the treatment of HIV infection
82. Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells
83. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection
84. Phosphatidylserine-mediated phagocytosis of influenza A virus infected cells by mouse peritoneal macrophages
85. Role of macrophages in restricting herpes simplex virus type I growth after ocular infection
86. Liposomes
87. Liposomal delivery of biological modifiers to macrophages
88. Liposome encapsulated muramyl tripeptide: A new biological response modifier for the treatment of osteosarcoma
89. Liposomal vaccines: Clinical status and immunological presentation for humoral and cellular immunity
90. Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophages colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare
91. Effect of liposome-encapsulated ciprofloxacin on phagocytosis, nitric oxide and intracellular killing of Staphylococcus aureus by murine macrophages
92. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin
93. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti HIV-1 activity, tissue distribution and pharmacokinetics
94. Inhibition of HIV-1 in monocyte/macrophages cultures by 2,3-dideoxycytidine-5-triphosphate, free and in liposomes
95. Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH-sensitive liposomes
96. Highly loaded nanoparticulate carrier using a hydrophobic antisense oligonucleotide complex
97. Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen induced arthritis
98. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin
99. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer
100. Phase II study of liposomal doxorubicin in platinum and paclitaxel-refractory epithelial ovarian cancer
101. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma
102. Liposome encapsulated aminoglycosides in pre-clinical and clinical trial
103. Efficacy of liposomal muramyltripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma
104. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for retractable melanoma in patients who were at high risk for relapse: An update
105. Theory and practice of site-specific drug delivery